Live Breaking News & Updates on Upcoming Milestones|Page 6

Stay updated with breaking news from Upcoming milestones. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Risvodetinib Risvo , Miltonh Werner , Risvodetinib Ik , Company Contact , Exchange Commission , Inhibikase Therapeutics Inc , Division Of Hematologic Malignancies , Steam Review , Inhibikase Or Company , Alex Lobostern Investor Relations Inc , Abelson Tyrosine Kinases , Chief Executive Officer , Upcoming Milestones , Hematologic Malignancies , Meeting Minutes , Review Team , Older Adults , Call Informationinhibikase , Inhibikase Therapeutics , Abelson Tyrosine Kinase , Abelson Tyrosine , Multiple System Atrophy , Media Disclaimerinvestors , Looking Statementsthis , Private Securities Litigation Reform Act ,

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Kiora Pharmaceuticals, Inc. today announced its 2023 financial results and provided an update on its retinal disease development pipeline. The Company s major initiatives planned for 2024 are to. ....

Brianm Strem , California Newsfile Corp , Kiora Pharmaceuticals Inc , Kiora Pharmaceuticals , Open Innovation , Melissa Tosca , Upcoming Milestones , Orphan Drug Designations , Private Securities Litigation Reform Act , Annual Report ,

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Brianm Strem , Dennis Riedl , Kiora Pharmaceuticals Inc , California Newsfile Corp , Kiora Pharmaceuticals , Open Innovation , Melissa Tosca , Upcoming Milestones , Orphan Drug Designations , Private Securities Litigation Reform Act , Annual Report ,

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

$40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 2025

Completed enrollment of Phase 2 clinical study of EQ101 in alopecia areata: topline data expected in Q2. ....

New Zealand , Steve Connelly , Arash Mostaghimi , Harvard Medical School , Equillium Inc , Exchange Commission , Ono Pharmaceutical Co Ltd , Bioniz Therapeutics Inc , Bruce Steel , Investor Day , Annual Peptide Therapeutics Symposium , Upcoming Milestones , Full Year , Asset Purchase Agreement , Bioniz Therapeutics , Multi Cytokine Platform , Multi Cytokine Inhibitors , Biocon Limited , Private Securities Litigation Reform Act , Consolidated Statements ,

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial. ....

United Kingdom , United States , Black Diamond , Mark Velleca , Mario Corso , Diamond Therapeutics Inc , Drug Administration , Company Masterkey , European Organization For Research , American Association For Cancer Research , Ivy Brain Tumor Center , Development Expenses , Exchange Commission , National Cancer Institute , Diamond Therapeutics , Chief Executive Officer , Upcoming Milestones , European Organization , Cancer Research , Molecular Targets , Cancer Therapeutics , American Association , Administrative Expenses , Private Securities Litigation Reform Act , Annual Report , United States Securities ,